| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
BAY-Y 3118 targets bacterial enzymes DNA gyrase and topoisomerase IV, which are essential for DNA replication and repair. These enzymes are critical for maintaining DNA supercoiling and chromosome segregation during bacterial cell division. By inhibiting DNA gyrase and topoisomerase IV, BAY-Y 3118 prevents bacterial DNA replication, ultimately leading to bacterial cell death. As a fluoroquinolone antibiotic, it belongs to a well-established class of antibacterial agents.
|
|---|---|
| ln Vitro |
Acinetobacter baumannii, Xanthomonas maltomonas, Haemophilus influenzae, Moraxella catarrhalis, Gram-positive cocci, and anaerobic bacteria are among the strains against which BAY-Y 3118 is effective; its MIC (MIC50) and MIC90, which represent 50% of the strains, are ≤0.015 and ≤0.015, ≤0.015 and ≤0.015, 0.03 and 2, 0.25 and 0.5, 0.06 and 1, 0.12 and 0.25 μg/mL[1]. At extracellular concentrations ranging from 2 to 100 mg/L, BAY-Y 3118's cellular to extracellular concentration ratio was more than 6.3. BAY-Y 3118 is absorbed quickly, reversibly, and unsaturatedly. Cell viability and ambient temperature have a major impact on BAY-Y 3118's capacity to penetrate cells inside of them. Human polymorphonuclear leukocytes (PMN) contain substantial intracellular quantities of BAY-Y 3118, which is still active within the cells [2]. All strains of Listeria spp., including Listeria monocytogenes. Extremely sensitive; these organisms have a MIC range of 0.062 to 0.25 μg/mL. In vitro, BAY-Y 3118 exhibits a fast bactericidal action, exhibiting post-antibiotic effects within 3 hours of antibiotic withdrawal. Infected L929 cells treated with BAY-Y 3118 showed the elimination of Listeria monocytogenes, suggesting that the compound had a bactericidal effect on Listeria in these cells [3].
BAY-Y 3118 demonstrates potent in vitro antimicrobial activity against a broad spectrum of pathogens, including Gram-negative and Gram-positive bacteria, as well as anaerobic and intracellular bacteria. It is rapidly bactericidal in vitro, with a postantibiotic effect occurring for 3 hours after removal of the antibiotic. The compound eliminates Listeria monocytogenes from infected L929 cells, suggesting a bactericidal effect on the listeriae in these cells. It has shown promise in preclinical studies for treating challenging infections, particularly respiratory and urinary tract infections. |
| ln Vivo |
Treating immunocompetent mice with 4 mg every 12 hours resulted in a quick recovery. Simultaneously, the mouse serum's levels of gamma interferon and interleukin-6 dropped quickly. Compared to treating immunocompetent mice with 2 mg of ampicillin every 12 hours, treating them with 2 mg of BAY-Y 3118 every 12 hours produced a larger initial reduction in organ Listeria counts. Listeria monocytogenes in the liver and spleen of chronically infected nude mice are totally eradicated by BAY-Y 3118 [3].
BAY-Y 3118 has shown in vivo efficacy in animal models of infection. Listeria monocytogenes is eliminated from infected mice treated with BAY-Y 3118. The compound's efficacy against drug-resistant pathogens makes it a valuable candidate in the search for effective antibacterial therapies. Its activity against intracellular bacteria suggests it may be effective against pathogens that reside within host cells, such as Listeria. Specific dosing regimens and efficacy data from animal models are not detailed in the available sources. |
| Enzyme Assay |
The antibacterial activity of BAY-Y 3118 is assessed using standard broth microdilution assays to determine the minimum inhibitory concentration (MIC). Bacterial strains (including Gram-positive and Gram-negative pathogens) are grown in cation-adjusted Mueller-Hinton broth. Two-fold serial dilutions of BAY-Y 3118 are prepared in 96-well plates, and bacterial suspensions are added to achieve a final inoculum of approximately 5×10⁵ CFU/mL. Plates are incubated at 35-37°C for 18-24 hours, and the MIC is determined as the lowest concentration that inhibits visible bacterial growth. The compound's activity against intracellular bacteria is assessed using infected cell lines such as L929 cells.
|
| Cell Assay |
To evaluate the intracellular activity of BAY-Y 3118, eukaryotic cells (such as L929 fibroblasts) are infected with intracellular bacteria (e.g., Listeria monocytogenes). After infection, the cells are treated with varying concentrations of BAY-Y 3118 for a specified period. The cells are then lysed, and the number of viable intracellular bacteria is determined by plating serial dilutions on agar plates and counting CFU. The compound's ability to eliminate intracellular bacteria is expressed as the log10 reduction in CFU compared to untreated controls. Extracellular bacteria are killed by the addition of gentamicin to ensure only intracellular bacteria are counted.
|
| Animal Protocol |
The in vivo efficacy of BAY-Y 3118 is evaluated in mouse models of bacterial infection. Immunocompetent mice are infected with a bacterial pathogen (e.g., Listeria monocytogenes) via intravenous or intraperitoneal injection. After infection, mice are treated with BAY-Y 3118 at various doses, typically administered orally or intravenously. At the end of the treatment period (e.g., 24-72 hours post-infection), animals are euthanized, and target organs (e.g., spleen, liver) are collected. The bacterial load in these organs is determined by homogenizing the tissue and plating serial dilutions on agar plates to count CFU. Efficacy is expressed as the log10 reduction in CFU compared to the untreated control group.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for BAY-Y 3118 are not provided in the available sources. The compound is a small molecule with a molecular weight of 405.85 and is soluble in DMSO. As a fluoroquinolone antibiotic, it is expected to have favorable oral bioavailability and tissue distribution. Standard pharmacokinetic studies would typically involve administering the compound to rodents and measuring plasma and tissue concentrations over time using LC-MS/MS. The compound is stored at -20°C.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for BAY-Y 3118 are not provided in the available sources. As a fluoroquinolone antibiotic, its toxicity profile is expected to be similar to other members of this drug class. The compound is intended for research use only and is not approved for human therapeutic applications. Standard safety precautions should be followed when handling this compound, including the use of appropriate personal protective equipment.
|
| References |
[1]. Fass RJ, et al. In vitro activity of Bay y 3118, a new quinolone. Antimicrob Agents Chemother. 1993 Nov;37(11):2348-57.
[2]. García I, et al. Intracellular penetration and activity of BAY Y 3118 in human polymorphonuclear leukocytes. Antimicrob Agents Chemother. 1994 Oct;38(10):2426-9. [3]. Nichterlein T, et al. Bay Y 3118, a new quinolone derivative, rapidly eradicates Listeria monocytogenes from infected mice and L929 cells. Antimicrob Agents Chemother. 1994 Jul;38(7):1501-6 |
| Additional Infomation |
See other relationships...
BAY-Y 3118 is a new chlorofluoroquinolone with antimicrobial activity. It is a synthetic fluoroquinolone antibiotic with potent activity against gram-positive and gram-negative bacteria. The compound operates by inhibiting bacterial enzymes DNA gyrase and topoisomerase IV. It has shown promise in preclinical studies for treating challenging infections, especially respiratory and urinary tract infections. Its efficacy against drug-resistant pathogens makes it a valuable candidate in antibacterial research. |
| Molecular Formula |
C20H21CLFN3O3
|
|---|---|
| Molecular Weight |
405.850447416306
|
| Exact Mass |
405.125
|
| CAS # |
151213-16-0
|
| Related CAS # |
(R,R)-BAY-Y 3118;151213-22-8
|
| PubChem CID |
119375
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
627.2±55.0 °C at 760 mmHg
|
| Flash Point |
333.1±31.5 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.654
|
| LogP |
2.05
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
28
|
| Complexity |
715
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N(C4)C[C@]5([H])[C@@]4([H])CCCN5)=C3Cl)C1=O)O
|
| InChi Key |
VRXORHRXNRJZCQ-ZUZCIYMTSA-N
|
| InChi Code |
InChI=1S/C20H21ClFN3O3/c21-16-17-12(19(26)13(20(27)28)8-25(17)11-3-4-11)6-14(22)18(16)24-7-10-2-1-5-23-15(10)9-24/h6,8,10-11,15,23H,1-5,7,9H2,(H,27,28)/t10-,15+/m0/s1
|
| Chemical Name |
7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
|
| Synonyms |
BAY-Y 3118; BAY-Y-3118; BAY Y 3118;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~82.12 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.16 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.16 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4640 mL | 12.3198 mL | 24.6396 mL | |
| 5 mM | 0.4928 mL | 2.4640 mL | 4.9279 mL | |
| 10 mM | 0.2464 mL | 1.2320 mL | 2.4640 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA